Kymera Therapeutics (KYMR) Company presentation summary

Platform and market opportunity

• Targeted protein degradation uses E3 ligases to drive target-protein degradation; its catalytic action may enable sustained pathway blockade with lower or shorter drug exposure than conventional inhibitors.

• The presentation targets historically undrugged, genetically or clinically validated pathways, aiming to pair oral convenience with biologics-like activity.

• An estimated 160M patients across the US, EU5 and Japan have diagnosed immunological diseases; about 5M receive advanced systemic therapies, in markets forecast to exceed $100B in annual sales.

• Advanced systemic immunology treatments are predominantly injectable biologics; cited research found over 90% of surveyed patients would switch to an oral option.

Pipeline and milestones

• Wholly owned oral degrader programs include STAT6 candidate KT-621 for Type 2 diseases and IRF5 candidate KT-579 for autoimmune diseases; KT-621’s estimated patient opportunity exceeds 140M and KT-579’s exceeds 10M.

• KT-621 Phase 2b AD data are expected by year-end 2026; Phase 3 AD trials are planned to start by mid-2027, while Phase 2b asthma data are expected late 2027.

• KT-579’s LUMORA Phase 1b lupus trial is planned to start by early 2027; KT-485 and KT-200 are partnered IRAK4 and CDK2 degrader programs, respectively.

• Sanofi initiated KT-485 Phase 1 testing in healthy volunteers and hidradenitis suppurativa patients; Gilead plans IND-enabling work on KT-200 to support an IND filing in 2027.

KT-621 clinical profile

• In the 22-patient, 28-day Phase 1b AD study, median STAT6 degradation reached 98% in blood and 94% in skin across dose groups; skin degradation was maintained through treatment.

• At Day 29, overall mean EASI change was -63%, EASI-50 response was 76%, and EASI-75 response was 29%; mean Peak Pruritus NRS change was -40%.

• Type 2 biomarker reductions included 74% median TARC inhibition and 73% Eotaxin-3 inhibition; in AD patients with comorbid asthma, median FeNO fell 56% at Day 29, with all four patients meeting the ACQ-5 responder threshold.

• The Phase 1b study reported no serious or severe adverse events, no related treatment-emergent events leading to discontinuation, and no clinically relevant vital-sign, laboratory or ECG changes.

• Phase 1 results were described as in line with, or in some cases numerically above, published dupilumab Week 4 data; comparisons are cross-trial, not head-to-head, and may not be reliable.